Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).
Scott N. Gettinger
Consultant or Advisory Role - ARIAD
Honoraria - ARIAD
Research Funding - ARIAD
Lyudmila Bazhenova
No relevant relationships to disclose
Ravi Salgia
No relevant relationships to disclose
Corey J. Langer
Research Funding - ARIAD
Kathryn A. Gold
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD
Glen J. Weiss
Honoraria - Celgene; Genentech; Medscape; Pfizer; Quintiles
Narayana I. Narasimhan
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
David J. Dorer
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Other Remuneration - ARIAD
Victor M. Rivera
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Tim Clackson
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Frank G. Haluska
Employment or Leadership Position - ARIAD
Consultant or Advisory Role - ARIAD (I)
Stock Ownership - ARIAD
Honoraria - Lia Gore (I)
Research Funding - ARIAD
D. Ross Camidge
Honoraria - ARIAD
Research Funding - ARIAD